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Abstract Analysis of sentinel lymph node (SLN) by means
of One-Step Nucleic Acid Amplification (OSNA) is being
used increasingly as a very sensitive and quick method for
intraoperative axillary staging in patients with breast cancer.
Thismoleculardiagnosticassaydetectstheexpressionlevelof
cytokeratin19 (CK19), a luminal epithelialcell marker broad-
ly expressed in most breast carcinomas and not normally
found in lymph nodes. Almost all breast cancers express this
cytoskeleton protein, but some breast tumorshave been found
tolosetheexpressionofCK19.CK19immunostainingincore
biopsies has been recommended in selecting patients eligible
for OSNA analysis because SLNs with metastatic involve-
ment by CK19-negative breast cancers may result in a false
negative result by OSNA. However, the real frequency of
CK19-negative breast cancer has to be elucidated. In this
study, we have assessed the frequency and molecular profile
of CK19-negative breast carcinomas in three series of cases.
The first is a prospective series of 197 breast carcinomas, 111
of which were subjected to SLN evaluation by OSNA. The
second is a retrospective series of 41 triple-negative (TN)
breast carcinomas, and the third is a retrospective series of
68 breast cancer patients (matched core biopsies and meta-
static lymph nodes) that had been evaluated by conventional
proceduresbeforetheOSNAmethodologywasadoptedinour
institution. Our results not only demonstrate that lack of
expression of CK19 is infrequent in breast cancers but also
that performing CK19 immunohistochemical staining is im-
portant on diagnostic core biopsies in taking the decision of
using OSNA methodology in the evaluation of sentinel nodes
in breast cancer patients.
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Introduction
In the last 10 years, breast carcinoma has been categorized by
means of cDNA microarray studies [1, 2]i nf i v es u b t y p e s :
luminal A and B, Her2, basal-like, and the more controversial
normal breastlike. Luminal breast cancers show high expres-
sionlevelsofseveral luminal epithelialcell markerslikeCK7,
CK8, CK18 and CK19, MUC1, bcl-2, estrogen receptors
(ER), progesterone receptors (PR), GATA3, epithelial cell
adhesion molecules, and lower expression levels of basal
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DOI 10.1007/s00428-012-1241-zCKs(CK5,CK14,andCK17).Incontrast,breastcancerswith
a basal-like phenotype [3] are characterized by a protein
expression pattern which is similar to that of myoepithelial
cells, including a higher expression of high molecular weight
cytokeratins, such as CK5, CK14 and CK17, smooth muscle
markers, p63, CD10, EGFR/HER1, or beta-4 integrin, among
others, and a lower expression of ER, PR, or HER2.
Currently, in clinical practice, the cytokeratin expression
pattern of breast tumors usually is not assessed, and breast
cancers are, as a rule, immunohistochemically classified into
four immunophenotypes with very important implications [4,
5] inorder to decide the more appropriate therapeutic approach:
luminal A (ER+and/or PR+, HER2−), luminal B (ER+and/or
PR+, and Ki67>14 % or HER2+), HER2 overexpressing
(ER−,P R −, HER2+), and triple-negative (TN) phenotype
(ER−,P R −,H E R 2 −)[ 6]. Most TN breast cancers fit within
the basal-like subgroup, although these two terms are not
synonymous, and immunohistochemical assessment of EGFR
and basal cytokeratins 5 and 6 is usually needed for better
profiling of the basal-like phenotype among the TN tumors [7].
Sentinel lymph node (SLN) analysis by means of the One-
Step Nucleic Acid Amplification (OSNA) assay is an increas-
ingly used procedure for intraoperative staging of breast can-
cer patients [8]. The OSNA assay [9] (Sysmex, Kobe, Japan)
is based on real-time amplification and quantitation of CK19
mRNA in homogenized samples of lymph nodes. In spite of
the differences in cytokeratin expression pattern between lu-
minalandbasal-likebreastcancers,luminalCK19waschosen
as the most suitable marker for identifying breast cancer
metastases in lymph nodes by means of OSNA because
virtually all (98.2 %) primary breast cancers were found to
express this cytoskeletal protein [10]. CK19 mRNA has been
described as having the highest sensitivity at nearly 90 % and
was chosen as the best marker for OSNA assay among 45
potential mRNAs [8]. However, CK19 is not expressed in a
small proportionofbreastcarcinomasincluding tumorswitha
luminal phenotype. Abd El-Rehim reported in 2004 [11]a
consecutive series of 1944 breast carcinomas with 3.4 % (42/
1230) of ER-positive tumors lacking CK19 expression. Sim-
ilarly, Parikh et al. [12] reported in a cohort of 158 young
women with stage I/II breast cancer, absence of CK19 expres-
sion in 6 % (4/66), and 30 % (21/62) of carcinomas with non-
TN and TN phenotype, respectively.
In our institution, OSNA procedure is complemented
with touch imprints as a quality control procedure. Between
February 2009 and April 2011, nearly 450 breast carcinomas
have been subjected simultaneously to OSNA and touch
imprints. Concordant results were obtained in all but 13 of
the cases, including three cases with isolated cells, eight cases
with micrometastases, and one case with macrometastases, all
of them regarded as negative by means of the touch imprints.
O n em o r ed i s c r e p a n tc a s er e s u l t e di naS L Nw i t hm a l i g n a n t
cellsobservedinthe touchimprintsbut notdetectedbyOSNA.
This case turned out to be a grade I CK19-negative breast
carcinoma with a luminal A immunophenotype and showed a
high expression level of both ER and PR and a low Ki-67
proliferative index (4 %). The Her-2 expression was scored as
negative (1+). A lymph node metastasis was seen in a touch
imprint from the SLN but had not been detected by molecular
procedures. The absence of expression of CK19 was confirmed
bySysmexEuropeGmbH.Thediagnosticcorebiopsyobtained
several weeks before SLN analysis was also CK19-negative.
Since this case was found, we routinely checked the status of
CK19 in all newly diagnosed breast cancers on the diagnostic
core biopsy. When CK19 expression is confirmed in the core
biopsy, analysis of SLN is made by OSNA analysis in parallel
with a touch imprint. If CK19 is negative, analysis of SLN is
done by frozen section, touch imprints, and evaluation of
formalin-fixed and paraffin-embedded samples, stained with
hematoxylin and eosin (H&E), and immunostained with the
pan-cytokeratin antibody AE1/AE3.
In order to assess the practical consequences of the ab-
sence of CK19 expression in breast cancer and to validate
our strategy, we have conducted a prospective and retro-
spective study in order to determine the frequency of CK19-
negative tumors within each of the four distinct immuno-
phenotypes of breast carcinoma. Our results support the
notion that the absence of expression of CK19 is rare in
breast cancer but does occur in carcinomas with either a
luminal or basal-like phenotype. Therefore, evaluation of
CK19 in the diagnostic core biopsy may help in taking the
decision as to the use of OSNA methodology in the evalu-
ation of sentinel nodes in breast cancer patients.
Materials and methods
Patients and tumor specimens
Three different series of cases were studied. The first is a
prospective consecutive series of 197 breast cancer core biop-
sies of patients who were diagnosed in Hospital Universitari
ArnaudeVilanova,Lleida,SpainbetweenApril2010andApril
2011. The mean age was 62.0 years (range 30 to 96 years). The
histology of the cases included 182 (92.4 %) ductal breast
carcinomas NOS, six (3.0 %) lobular breast carcinomas, and
nine (4.6 %) belonging to other histologic subtypes. Tumor
mean size was 18.2 mm. From them, 111 patients were sub-
jected to sentinel node biopsy and OSNA evaluation.
Secondly, a retrospective series that included 41 TN
breast carcinomas surgically resected from 2000 through
2010 was evaluated for CK5/6 and EGFR to identify breast
cancers that have a basal-like phenotype. Subsequently, the
CK19 status was checked in all the tumors from this series.
Thirdly, we included a retrospective series of 68 patients
in which SLN was found to be positive for metastasis by
570 Virchows Arch (2012) 460:569–575conventional pathological examination (touch imprints, frozen
sections, and H&E and cytokeratin expression in formalin-
fixedparaffin-embeddedmaterial)beforetheOSNAprocedure
was implemented in our institution on February 2009.Material
available for these cases included sentinel node specimen and
matched primary tumors.
OSNA
The OSNA assay for CK19 mRNA was introduced in our
pathology department on February of 2009 as a routine
method for analysis of SLN of breast cancer patients after
a multicentric validation study performed under the auspices
of Sociedad Española de Senología [12]. Between April
2010 and April 2011, 111 breast cancer patients from the
first series were subjected to OSNA analysis of sentinel
node. The OSNA protocol consisted of homogenization of
tissue in a mRNA-stabilizing solution (Lynorhag, pH 3.5
Sysmex®) and subsequent isothermal (65 °C) amplification
of cytokeratin 19 (CK19) using the Lynoamp amplification
kit (Sysmex®) through a reverse transcriptase amplification
assay (RT-LAMP) in a gene amplification detector RD-100i
(Sysmex®) in compliance with the protocol previously de-
scribed [8, 9]. The technique uses six primers, which in-
crease the specificity and the speed of the reaction. In the
OSNA assay, cases showing mRNA CK19 levels greater
than 250 copies/μL were considered positive and were
classified as micrometastases (number of copies >250 cop-
ies/μL <5,000 copies/μL) or macrometastases (number of
copies >5,000 copies/μL) following system specifications
based on prior calculations. Cases identified as “negative”
(<250 copies/μL) by the system were further classified as
isolated tumor cells (ITC) (no. of copies per microliter >100
but less than 250) or true negative if the number of copies
per microliter was <100.
ApositiveOSNAreactionwasfoundin54ofthe 111cases
of the first series (33 macrometastases, 19 micrometastases,
and two ITC). In all cases, the OSNA analysis has been
complemented with touch imprints, which are performed si-
multaneously with OSNA procedure. Concordance between
OSNA results and touch imprints was observed in all but one
of the patients, the latter corresponding to the first CK19-
negative breast cancer mentioned above.
Immunohistochemistry
ER, PR, Ki-67, and Her-2
The immunophenotype of the three series of tumors was
assessed in real time by means of immunolabeling for ER,
PR, Ki-67, and Her-2 on the diagnostic core biopsies. For
immunohistochemical analysis of ER, PR, and Ki-67 in the
prospective consecutive series, the tissue sections were
deparaffinized and endogenous peroxidase activity was
blocked with Peroxidase-Blocking Reagent for 10 min. For
ER and PR immunostaining, epitope retrieval was performed
by heating at 95 °C in Target Retrieval Solution, High pH
(50× Tris/EDTA buffer, pH 9) of Dako® for 20 min. The
slides were subsequently incubated for 25 min with monoclo-
nal mouse antihuman ERα antibody (clone 1D5, isotype
IgG1, kappa) for ER staining and with monoclonal mouse
antihumanPRantibody(clonePgR636,isotype IgG1, kappa)
for assessment of PR expression. The expression of ER and
PR was graded semiquantitatively by considering the percent-
age and intensity of the staining applying the following for-
mula: Histoscore01×(% light staining)+2×(% moderate
staining)+3×(% strong staining). The Allred score 7 is used
as well. In order to assess the proliferative index, antigen
retrieval was performed by heating at 95 °C in Target Retriev-
al Solution, High pH (50× Tris/EDTA buffer, pH 6.1) of
Dako® for 20 min and incubation with monoclonal mouse
antihuman Ki-67 antigen (clone MIB-1) for 20 min. Ki-67-
positive nuclei were scored in the tumor areas showing the
highest number of stained nuclei. In all cases, the slides were
incubated with EnVision™ FLEX of Dako® as secondary
antibody for 20 min, with chromogen diaminobenzidine tet-
rahydrochloride for 10 min and finally, counterstained with
hematoxylin, dehydrated with ethanol, and mounted. Her-2
immunolabeling was performed following the HercepTest™
of Dako®. The antigen retrieval was by heating at 97 °C for
40 min with HercepTest™ Epitope Retrieval Solution (con-
taining detergent 10×) (0.1 mol/L citrate buffer with a deter-
gent). The slides were incubated with the primary antibody
HercepTest™ Rabbit Anti-Human HER2 Protein for 30 min
and with HercepTest™ Visualization Reagent for 30 min as
secondary antibody.
Basal-like immunophenotype
All tumors which showed a TN phenotype were subsequent-
ly immunostained for EGFR and CK5/6 in order to charac-
terize them as “basal-like” or “non basal-like.” EGFR
immunostaining was performed using the kit EGFR
pharmDx of Dako®. The samples were digested for 5 min
with proteinase K for antigen retrieval and incubated for
30 min with the primary antibody Mouse Antihuman EGFR
protein. Subsequently, they were incubated for 30 min with
the secondary antibody Labelled Polymer-HRP. CK5/6 was
assessed by means of the PT Link Pre-treatment Module of
Dako®, using Target Retrieval Solution, High pH, for
20 min for antigen retrieval and a 20-min incubation with
the primary antibody Monoclonal Mouse Anti-Human clone
D5/16 B4. The slides were incubated with EnVision™
FLEX of Dako® as secondary antibody for 20 min. CK 5/
6 and EGFR were scored following qualitative criteria. TN
tumors showing either CK5/6 or EGFR expression, even
Virchows Arch (2012) 460:569–575 571if focal, were regarded as tumors with a “basal-like”
phenotype [7].
CK19 immunostaining
Finally, CK19 was assessed by incubation with the RCK108
primary antibody for 20 min. Methodology was similar to
that performed for ER and PR, and the samples were incu-
bated with EnVision™ FLEX of Dako® as secondary anti-
body for 20 min.
Statistics
For statistical evaluation of the data reported in Table 2, the
Statistical Package for Social Science (SPSS) software was
used. The contingency tables for clinicopathological corre-
lations were analyzed by means the χ
2 test.
Results
Results are summarized in Tables 1 and 2.
Prospective series of 197 breast carcinomas
First, we evaluated a prospective series of 202 consecutive,
unselected breast cancers, 111 of which were subjected to
SLN evaluation by OSNA. In that series, the expression of
CK19 had been assessed in 197 cases. This series comprised
57 (28.9 %) luminal A cases (ER+and/or PR+, Ki67<14 %,
Her2−), 103 (52.3 %) luminal B cases (ER+and/or PR+,
Ki67>14 % or Her2+), 14 (7.1 %) Her2 cases (ER−,P R −,
Her-2+), and 23 (11.7 %) TN cases, with 16 (7.9 %) basal-
like tumors by means of immunolabeling with CK5/6 and
EGFR.
In this series, a total of six (3.04 %) CK19-negative
breast carcinomas were found. Five of the six carcinomas
lacking CK19 expression were positive for ER and regarded
as carcinomas with a luminal phenotype (5/160, 3.1 %), two
of them with a luminal A phenotype and the remaining three
with a luminal B phenotype. The sixth CK19-negative case
was a TN carcinoma, with a basal-like phenotype (1/24,
4.2 %). The first luminal-type carcinoma was the case
described in the “Introduction,” a grade I breast carcinoma
with high expression of ER and PR, low Ki67 index (lumi-
nal A), and a metastatic sentinel node that was misinter-
preted by OSNA. The second CK19-negative case, with a
luminal A phenotype, was not treated in our center. In the
third luminal-type tumor (luminal B), lymph node metasta-
ses were demonstrated by means an axillary fine-needle
aspiration as well as in the basal-like one. In the fourth
and fifth luminal carcinomas (luminal B) lacking expression
of CK19, the SLNs were examined by means of frozen and
paraffin-embedded sections. Such a decision was taken after
CK19 staining turned out negative in the diagnostic core
biopsy. A micrometastasis was detected in one case by
means of immunolabeling for cytokeratins using the AE1/
AE3 antibody and a macrometastasis (9 mm) in the other
case, which was seen in the frozen section. Then, we
checked the expression of CK19 in these two metastases.
Table 1 Characteristics of the prospective series of 197 breast cancer
cases in which CK19 expression has been assessed
Age (years)
Mean 62.05
Median±SD 63±15.25
Range 30–96
Histology
Ductal 182 (92.4 %)
Lobular 6 (3.0 %)
Other 9 (4.6 %)
Tumor size (mm)
Mean 18.2
T1 (<2.0) 110
≥T2 (≥2.0) 54
Tumor grade
Grade I 56 (28.4 %)
Grade II 104 (52.7 %)
Grade III 15 (7.6 %)
NA 22
Nodal status
Total assessed 174 (87.9 %)
Negative 77 (38.9 %)
Positive 97 (49.0 %)
ER status
Negative 37 (18.8 %)
Positive 160 (81.2 %)
Her2 status
Negative 170 (86.3 %)
Positive 27 (13.7 %)
Ki67
Low (<14 %) 61 (31.0 %)
High (>14 %) 136 (69.0 %)
Immunophenotype
Luminal
—Luminal A 57 (28.9 %)
—Luminal B (ER+and Her2+ or Ki67>14 %) 103 (52.3 %)
—Total luminal 160 (81.2 %)
Her-2 14 (7.1 %)
Triple-negative 23 (11.7 %)
Cytokeratin 19 status
Positive 191 (96.5 %)
Negative 6 (3.0 %)
Undone 5 (0.5 %)
572 Virchows Arch (2012) 460:569–575The micrometastasis from the fourth CK19-negative luminal
tumor was CK19-negative as well. The macrometastasis
from the fifth CK19-negative luminal carcinoma, however,
showed some isolated CK19-positive cells (Fig. 1). When
the immunohistochemical profile of the tumors had been
initially assessed in core biopsies samples, we compared this
with the CK19 status of this primary tumor on the surgical
specimen to rule out the possibility that the core biopsy was
not representative for the whole tumor in terms of CK19
expression. This primary carcinoma was mostly CK19-
negative, but there were some small areas with immunolab-
eling for CK19, and these areas were not present in the core
biopsy.
Retrospective series of 41 triple-negative (TN) breast
carcinomas
The series of 41 TN breast carcinomas consisted of 30
tumors with a basal-like phenotype and nine carcinomas
with a nonbasal-like TN phenotype. In two cases, we could
not test retrospectively the expression of CK5/6 and EGFR
in order to further characterize these as basal-like or “non-
basal-like. No tumor from this series was CK19-negative.
Retrospective series of 68 cases with metastases in SLN
before OSNA implementation
SLN was evaluated in 211 breast cancer cases before the
OSNA methodology was adopted in our institution. All the
SLNs had been studied by means conventional pathological
and immunohistochemical examination, and the cases were
retrospectively reviewed in order to find CK19-negative
metastases which could have originated false negative
results by OSNA. Eighty-six SLNs had been positive for
metastasis, 23 with micrometastases, and 63 with macro-
metastases, but in 18 cases, the metastatic focus was
exhausted in the remaining material. Of the other 68 cases
with metastatic foci still present, all but one case was CK19-
positive. In this case, the expression of CK19 was checked
in the surgical specimen of the matched primary tumor, and
the tumor was homogeneously CK19-negative.
Discussion
The OSNA methodology for detection of axillary metastasis
in breast cancer is becoming a standard procedure and is
based on measuring the expression level of CK19 in the
SLN. CK19 was chosen as the optimal molecule because of
i t sb r o a de x p r e s s i o ni nm o s tb reast carcinomas, without
notable expression in hematopoietic cells [10]. Validation
studies published to date [13–17] show that OSNA is a
reliable quantitative test of intraoperative metastasis detec-
tion in SLNs of breast cancer patients.
In general, breast cancer is regarded to arise from luminal
epithelial cells of the terminal duct lobular unit (TDLU)
which express several cytokeratins such as CK7, CK8,
CK18, and CK19 [1]. This suggests that virtually all breast
carcinomas express CK19, but still there is the possibility
that some breast cancers loose CK19 expression during
tumor development and progression. This may be a chal-
lenge for the accuracy of OSNA in evaluating SLN. More-
over, a smaller group of breast carcinomas express some
Table 2 Association between CK19 status and patient features
CK19 status
Positive Negative p value
Age (years)
<Mean 89 2 0.048
>Mean 102 4
Histology
Ductal (NOS) 176 6 0.920
Lobular 6 0
Other 9 0
Tumor size (cm)
T1 (<2.0) 105 5 0.249
T2 (≥2.0) 54 0
Tumor grade
Grade I 54 2 0.123
Grade II 101 3
Grade III 15 1
Nodal status
Negative 77 0 0.096
Positive 92 5
ER status
Negative 36 1 0.000
Positive 155 5
Her2 status
Negative 161 6 0.036
Positive 27 0
Triple-negative status
Positive 22 1 0.791
Negative 169 5
Immunophenotype
Luminal A (ER+, Ki67<14 %, Her-2−) 55 2 0.754
Luminal B (ER+, Ki67>14 %
or Her-2+)
100 3
Her-2 14 0
Triple-Negative 22 1
Immunophenotype
Luminal A and B 155 5 0.000
Her-2 14 0
Triple-negative 22 1
Virchows Arch (2012) 460:569–575 573cytokeratins normally found in the outer basal layer of
myoepithelial cells of the mammary ductules, such as
CK5, CK14, and CK17, and, for this reason, are designated
basal-like [3, 6]. Consequently, breast cancers lacking CK19
expression might occur only in the basal-like subtype of
breast cancer or might also contain luminal breast carcino-
mas with loss of CK19 expression.
A few studies have addressed the frequency of CK19-
negative breast cancers. Parikh et al. (2008) [12] reported
lack of CK19 expression in 20.5 % of 158 breast carcinomas
in a tissue microarray. Moreover, they found a statistically
significant association between lack of CK19 expression
and the TN phenotype (30 % of TN breast cancers were
CK19-negative). However, four of their 27 CK19-negative
tumorswerenottriple-negative,whichintheirseriesamounted
to 6 %. Similarly, Abd El-Rehim et al. (2004) [11] reported
lack of CK19 expression in 3.4 % of luminal (ER+) breast
cancers. Very recent works [18] have assessed the expression
of CK19 in different histological types of breast cancer but
without consideration of their molecular profile.
A case of discordance between metastatic cells seen in a
touch imprint of a SNL but not detected by means of the
OSNA assay, allowed us to find a grade I ductal carcinoma
with a luminal A phenotype which did not express CK19.
The lack of CK19 expression was confirmed by Sysmex
Europe GmbH. From then on, we assessed the CK19 status
of all newly diagnosed breast carcinomas. To date, from a
consecutive series of 197 breast cancers in which CK19
expression was assessed, we found lack of CK19 expression
in 3.5 % (2/57) of breast cancers with a luminal A
phenotype (ER/PR+, Her2−, Ki67<14 %), 2.9 % (3/103)
of breast cancers with a luminal B phenotype (ER/PR+and
Ki67>14 % or Her2+), and 4.2 % (1/24) in triple-negative
carcinomas. We did not find any CK19-negative tumor with
a pure Her2-positive phenotype. We conclude from these
results and literature review that absence of CK19 expres-
sion can be expected in around 4 % to 7 % of breast
carcinomas with either a luminal or nontriple-negative phe-
notype (which can include the Her2 phenotype). It is con-
ceivable that in some breast cancers, the lack of CK19
expression might be due to an absence of translation of the
transcript CK19 mRNA. In these cases, the OSNA assay
would be able to detect and amplify CK19 mRNA in the
absence of protein. Nonetheless, it seems rational to check,
as a rule, the expression of CK19 by immunohistochemistry
in all newly diagnosed breast carcinomas in order to decide
whether the analysis of SLN should preferably be done
using the OSNA assay or conventional procedures. In one
of the five luminal carcinomas lacking CK19 expression on
the core biopsy, a macrometastasis was found in the SLN by
means of cytology and frozen section examination. Just a
few isolated cells of this macrometastasis expressed CK19.
OSNA assay might have interpreted as isolated cells this
macrometastasis. Interestingly, in this case, evaluation of
CK19 in the surgical specimen also demonstrated the occa-
sional presence of CK19-positive cells, which had not been
seen in the diagnostic core biopsy, thus demonstrating that
CK19expressionheterogeneitycanalsobe anadditionalprob-
lem in the strategyof usingCK19 evaluationinthe corebiopsy
as an indicator of eligibility for OSNA evaluation in SLNs.
ab
d c
Fig. 1 Sentinel lymph node
from the fourth luminal A
CK19-negative breast carcino-
ma. a Lymph node section
showing a macrometastasis of
9 mm in maxim diameter. b
View of the metastatic popula-
tion of cells by means of
CKAE1/AE3 pan-cytokeratin
immunostaining of the same
section. CK19 immunostaining
of the same lymph node section
(c and d). Only a small propor-
tion of metastatic cells express
CK19. a H&E staining, original
magnification×40. b Original
magnification×200. c Original
magnification×40. d Original
magnification×200
574 Virchows Arch (2012) 460:569–575Furthermore, we decided to study retrospectively a series
of 68 breast cancer patients that underwent SLN evaluation
by conventional pathological assessment before OSNA as-
say was implemented in order to assess the number of cases
that might have been misinterpreted as negative had they
been assessed by OSNA because of lack of CK19 immu-
nostaining. We found one case of SLN metastasis which was
CK19-negative, which translates into a 1.4 % of false neg-
ative rate of SLN assessment using the OSNA assay. Inter-
estingly, in this case, CK19 was not expressed in the core
biopsy, suggesting that the absence of CK19 expression in
the SLN might have been predicted by the evaluation of the
core biopsy.
Based on our results, we conclude that even though the
overall prevalence of CK19-negative breast carcinomas is
very low, they do occur not only in tumors with a triple-
negative or basal-like phenotype but also in breast cancers
with a luminal phenotype, in which expression of luminal
cytokeratins including CK19 is expected to be the rule.
Therefore, expression of CK19 should be routinely assessed
in all newly diagnosed primary breast carcinomas in order to
decide whether the intraoperative axillary staging should be
performed by means of cytology and pan-cytokeratins
immunostaining on SLN sections or by means of real-time
amplification and quantitation of CK19.
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